Anthem (NYSE:ANTM – Get Rating) had its target price upped by research analysts at Mizuho from $510.00 to $545.00 in a research report issued on Wednesday, The Fly reports. Mizuho’s price target suggests a potential upside of 9.33% from the stock’s current price.
Other analysts also recently issued reports about the stock. UBS Group raised their target price on shares of Anthem from $477.00 to $541.00 and gave the stock a “buy” rating in a report on Tuesday, March 29th. Jefferies Financial Group raised their target price on shares of Anthem from $575.00 to $625.00 in a report on Thursday, April 21st. Morgan Stanley raised their target price on shares of Anthem from $518.00 to $607.00 and gave the stock an “overweight” rating in a report on Thursday, April 21st. Sanford C. Bernstein raised their target price on shares of Anthem from $559.00 to $574.00 in a report on Tuesday, January 11th. Finally, StockNews.com initiated coverage on shares of Anthem in a report on Thursday, March 31st. They set a “strong-buy” rating on the stock. Two research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $545.23.
Shares of NYSE:ANTM opened at $498.48 on Wednesday. The company has a market capitalization of $120.18 billion, a price-to-earnings ratio of 19.63, a P/E/G ratio of 1.41 and a beta of 0.97. The firm’s 50 day simple moving average is $487.92 and its 200 day simple moving average is $454.94. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.36 and a quick ratio of 1.36. Anthem has a fifty-two week low of $355.43 and a fifty-two week high of $533.68.
In other Anthem news, CAO Ronald W. Penczek sold 2,763 shares of the stock in a transaction that occurred on Monday, February 7th. The stock was sold at an average price of $453.48, for a total transaction of $1,252,965.24. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Ronald W. Penczek sold 2,423 shares of the company’s stock in a transaction that occurred on Thursday, March 3rd. The stock was sold at an average price of $463.68, for a total value of $1,123,496.64. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 22,889 shares of company stock worth $10,532,411. Company insiders own 0.27% of the company’s stock.
Several large investors have recently modified their holdings of ANTM. Morgan Stanley raised its position in shares of Anthem by 7.8% during the second quarter. Morgan Stanley now owns 1,568,625 shares of the company’s stock worth $598,899,000 after purchasing an additional 113,659 shares during the period. Moors & Cabot Inc. acquired a new position in shares of Anthem during the third quarter worth approximately $416,000. Advisory Services Network LLC raised its position in shares of Anthem by 2.6% during the third quarter. Advisory Services Network LLC now owns 4,485 shares of the company’s stock worth $1,672,000 after purchasing an additional 113 shares during the period. Banco Santander S.A. raised its position in Anthem by 6.7% in the 3rd quarter. Banco Santander S.A. now owns 10,697 shares of the company’s stock valued at $3,987,000 after buying an additional 674 shares during the last quarter. Finally, Keybank National Association OH raised its position in Anthem by 5.1% in the 3rd quarter. Keybank National Association OH now owns 9,657 shares of the company’s stock valued at $3,600,000 after buying an additional 465 shares during the last quarter. 84.28% of the stock is currently owned by institutional investors.
Anthem Company Profile (Get Rating)
Anthem, Inc, through its subsidiaries, operates as a health benefits company in the United States. It operates through four segments: Commercial & Specialty Business, Government Business, IngenioRx, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small groups, individuals, Medicaid, and Medicare markets.
Further Reading
- Get a free copy of the StockNews.com research report on Anthem (ANTM)
- 3 Earnings Plays With Big Move Potential
- There Are Weeds In The Garden At Scotts Miracle-Gro
- It’s Time For FuboTV to Stand Out in the Sea of Streaming
- 3M Stock is Worth a Look Because of the Company it Keeps
- Landstar Systems Stock Can Bottom Down Here
Receive News & Ratings for Anthem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthem and related companies with MarketBeat.com's FREE daily email newsletter.